The 2026 IPO market has sustained momentum into late September, with 109 deals raising $146.5 billion through mid-month amid broad participation from AI infrastructure, biotech, and select growth names. Recent pricings such as ADARx Pharmaceuticals and filings by Oura (targeting a $2.1 billion raise with roadshow activity) and Accelevation highlight continued access to capital, supported by institutional demand for scaled issuers despite selective valuation discipline. Postponements tied to yield-driven rate sensitivity and expectations mismatches have tempered the fall window, yet new S-1 activity and effective registrations signal pipeline depth ahead of year-end. Trader sentiment on near-term IPO completions reflects these execution risks and macro factors like Treasury yields and equity volatility, with resolution hinging on specific company timelines through December 31.